Evidence map›Paper›PMID 42266513›Full record

Observational studyDrug design, development and therapy2026

Efficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized by

Xiaoqian Wang, Fengxia Xue, Chunlian Zhang, Ruifang An, Hongjie Ruan, Liancheng Zhu, Liping Zhang, Qinping Liao

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04956419 (A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Fluconazole Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04956419 phase3unknown statusnot on this map

A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Fluconazole Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis (VVC)

TypeinterventionalSponsorJiangsu HengRui Medicine Co., Ltd.Ran2021 to 2021Enrolled322ConditionsAcute Vulvovaginal CandidiasisArmsSHR8008 capsule, Fluconazole capsule
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoqian WangDepartment of Gynecology, Beijing Tsinghua Changgung Hospital, Beijing, People's Republic of China.
Fengxia XueDepartment of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Chunlian ZhangDepartment of Gynecology, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, People's Republic of China.
Ruifang AnDepartment of Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Hongjie RuanDepartment of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, Nanjing, People's Republic of China.
Liancheng ZhuDepartment of Gynecology, The Affiliated Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.
Liping ZhangDepartment of Gynecology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, People's Republic of China.
Qinping LiaoDepartment of Gynecology, Beijing Tsinghua Changgung Hospital, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Oteseconazole, a novel selective fungal CYP51 inhibitor, demonstrated superior efficacy over fluconazole for severe vulvovaginal candidiasis (SVVC) in a phase 3 trial. However, whether the efficacy and safety of oteseconazole on SVVC varies by Patients and Methods: In this exploratory post hoc analysis of a phase 3 trial (NCT04956419), data were analyzed from patients with SVVC receiving oteseconazole (600 mg on day 1 and 450 mg on day 2) or fluconazole (150 mg on days 1 and 4). The primary outcome was therapeutic cure rate at day 28, assessed in subgroups categorized by Results: Of 319 patients categorized by Conclusion: Oteseconazole may offer benefits and is generally well tolerated in patients with SVVC, irrespective of

Indexed as

Antifungal AgentsCandidaCandidiasis, VulvovaginalTriazolesAdultClinical Trials, Phase III as TopicFemaleFluconazoleHumansImidazolesMicrobial Sensitivity TestsRandomized Controlled Trials as TopicThiophenesTreatment OutcomeAntifungal AgentsFluconazoleImidazolessertaconazoleThiophenesTriazolesCandida speciesoteseconazolepost hoc analysisprevious genital tract infectionsevere vulvovaginal candidiasis

Identifiers

PMID42266513
PMCPMC13245468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.